Patient-controlled Analgesic Pumps Market Growth & Trends
The global patient-controlled analgesic pumps market size is expected to reach USD 580.5 million by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.6% from 2021 to 2028. Patient-controlled Analgesic (PCA) pumps offer several advantages including fewer post-operative complications, improved quality of recovery, less sedation, and minimal use of medication. Also, PCA pumps are useful among patients that have a problem in taking oral medications. Thus, the rising adoption of the medical device among patients that are unable to take oral medications is expected to drive the market. In addition, the growing trend of home healthcare during the COVID-19 pandemic is also expected to propel market growth in the coming years.
Patient-controlled analgesic pumps have positive outcomes for the pediatric postsurgical population including increasing autonomy, simplifying pain relief in the postoperative period, and maintaining stable hemodynamics. Innovative PCA techniques such as PCRA, PCEA, and noninvasive forms of PCA have extended the options available for pain treatment and are estimated to have a positive impact on market growth. Advances in the pumps including variable-rate infusions that are calculated based on patient needs for analgesic along with improved patient monitoring are anticipated to enhance the use of such techniques during the forecast timeframe.
Rising cases of chronic pain disorders including cancer, rheumatoid arthritis, and fibromyalgia are anticipated to boost the market growth. For instance, as per the CDC, in 2019 around 20.4% of adults had chronic pain. Chronic pain increases with age and is highest among adults aged 65 and above. Hence, the rising occurrence of chronic pain among adults is anticipated to create robust growth opportunities in the market.
Patient-controlled Analgesic Pumps Market Report Highlights
North America accounted for the largest revenue share in 2020. Increased healthcare awareness among individuals about pain management is anticipated to fuel the regional growth
By type, the electronic segment accounted for the largest revenue share in 2020 owing to several benefits offered by electronic PCA
By application, the oncology segment accounted for the largest revenue share in 2020 owing to high usage of patient-controlled analgesic pumps in managing sustained cancer pain
The hospitals segment held the largest revenue share as hospital settings provide advanced treatment facilities and are equipped with technologically advanced medical devices
The home care settings segment is projected to expand at the fastest CAGR of 6.7% over the forecast period
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. By Type
- 1.1.2. By Application
- 1.1.3. By End Use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Application outlook
- 2.2.3. End-use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Patient-controlled Analgesic pumps Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Industry Value Chain Analysis
- 3.3.1. Reimbursement framework
- 3.4. Market Dynamics
- 3.4.1. Market driver analysis
- 3.4.1.1. Increasing incidence of chronic illness such as cancer and pain
- 3.4.1.2. Rising advantages of patient-controlled analgesic pumps
- 3.4.1.3. Technological advancements
- 3.4.2. Market restraint analysis
- 3.4.2.1. Stringent regulations and product recalls
- 3.5. Patient-controlled Analgesic pumps Market Analysis Tools
- 3.5.1. Industry analysis - Porter's
- 3.5.1.1. Supplier power
- 3.5.1.2. Buyer power
- 3.5.1.3. Substitution threat
- 3.5.1.4. Threat of new entrant
- 3.5.1.5. Competitive rivalry
- 3.5.2. PESTEL analysis
- 3.5.2.1. Political landscape
- 3.5.2.2. Technological landscape
- 3.5.2.3. Economic landscape
- 3.5.3. Major deals & strategic alliances analysis
- 3.5.4. Market entry strategies
Chapter 4. Patient-controlled Analgesic pumps Market: By Type Estimates & Trend Analysis
- 4.1. Definitions and Scope
- 4.1.1. Electronic
- 4.1.2. Mechanical
- 4.2. Type Market Share, 2021 & 2028
- 4.3. Segment Dashboard
- 4.4. Global Patient-controlled Analgesic pumps Market, by Type Outlook
- 4.4.1. Electronic
- 4.4.1.1. Electronic market estimates and forecast, 2016 - 2028 (USD Million)
- 4.4.2. Mechanical
- 4.4.2.1. Mechanical market estimates and forecast, 2016 - 2028 (USD Million)
Chapter 5. Patient-controlled Analgesic Pumps Market: By Application Estimates & Trend Analysis
- 5.1. Definitions and Scope
- 5.1.1. Diabetes
- 5.1.2. Gastroenterology
- 5.1.3. Oncology
- 5.1.4. Hematology
- 5.1.5. Others
- 5.2. Application Market Share, 2021 & 2028
- 5.3. Segment Dashboard
- 5.4. Global Patient-controlled Analgesic Pumps Market, By Application Outlook
- 5.4.1. Diabetes
- 5.4.1.1. Diabetes market estimates and forecast, 2016 - 2028 (USD Million)
- 5.4.2. Gastroenterology
- 5.4.2.1. Gastroenterology market estimates and forecast, 2016 - 2028 (USD Million)
- 5.4.3. Hematology
- 5.4.3.1. Hematology market estimates and forecast, 2016 - 2028 (USD Million)
- 5.4.4. Oncology
- 5.4.4.1. Oncology market estimates and forecast, 2016 - 2028 (USD Million)
- 5.4.5. Others
- 5.4.5.1. Others market estimates and forecast, 2016 - 2028 (USD Million)
Chapter 6. Patient-controlled Analgesic Pumps Market: By End Use Estimates & Trend Analysis
- 6.1. Definitions and Scope
- 6.1.1. Hospitals
- 6.1.2. Specialty Clinics
- 6.1.3. Ambulatory Surgical Centers
- 6.1.4. Homecare Settings
- 6.2. By End Use Market Share, 2021 & 2028
- 6.3. Segment Dashboard
- 6.4. Global Patient-controlled Analgesic Pumps Market, By End Use Outlook
- 6.4.1. Hospitals
- 6.4.1.1. Hospitals market estimates and forecast, 2016-2028 (USD Million)
- 6.4.2. Specialty clinics
- 6.4.2.1. Specialty clinics market estimates and forecast, 2016 - 2028 (USD Million)
- 6.4.3. Ambulatory surgical centers
- 6.4.3.1. Ambulatory surgical centers market estimates and forecast, 2016 - 2028 (USD Million)
- 6.4.4. Homecare Settings
- 6.4.4.1. Homecare settings market estimates and forecast, 2016 - 2028 (USD Million)
Chapter 7. Patient-controlled Analgesic Pumps Market: Regional Estimates & Trend Analysis
- 7.1. Country Market Share Analysis, 2021 & 2028
- 7.2. County Market Dashboard
- 7.3. Regional Market Snapshot
- 7.4. Regional Market Share and Leading Players, 2020
- 7.4.1. North America
- 7.4.2. Europe
- 7.4.3. Asia Pacific
- 7.4.4. Latin America
- 7.4.5. Middle East and Africa
- 7.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
- 7.5.1. North America
- 7.5.2. Europe
- 7.5.3. Asia Pacific
- 7.5.4. Latin America
- 7.5.5. Middle East and Africa
- 7.6. Market Size, & Forecasts, Volume and Trend Analysis, 2019 to 2028:
- 7.7. North America
- 7.7.1. Market estimates and forecast, 2016 - 2028 (USD Million)
- 7.7.2. U.S.
- 7.7.2.1. U.S. market estimates and forecast, 2016 - 2028 (USD Million)
- 7.7.3. Canada
- 7.7.3.1. Canada market estimates and forecast, 2016 - 2028 (USD Million)
- 7.8. Europe
- 7.8.1. Market estimates and forecast, 2016 - 2028 (USD Million)
- 7.8.2. U.K.
- 7.8.2.1. U.K. market estimates and forecast, 2016 - 2028 (USD Million)
- 7.8.3. Germany
- 7.8.3.1. Germany market estimates and forecast, 2016 - 2028 (USD Million)
- 7.8.4. France
- 7.8.4.1. France market estimates and forecast, 2016 - 2028 (USD Million)
- 7.8.5. Italy
- 7.8.5.1. Italy market estimates and forecast, 2016 - 2028 (USD Million)
- 7.8.6. Spain
- 7.8.6.1. Spain market estimates and forecast, 2016 - 2028 (USD Million)
- 7.9. Asia Pacific
- 7.9.1. Market estimates and forecast, 2016 - 2028 (USD Million)
- 7.9.2. Japan
- 7.9.2.1. Japan market estimates and forecast, 2016 - 2028 (USD Million)
- 7.9.3. China
- 7.9.3.1. China market estimates and forecast, 2016 - 2028 (USD Million)
- 7.9.4. India
- 7.9.4.1. India market estimates and forecast, 2016 - 2028 (USD Million)
- 7.9.5. South Korea
- 7.9.5.1. South Korea market estimates and forecast, 2016 - 2028 (USD Million)
- 7.9.6. Australia
- 7.9.6.1. Australia market estimates and forecast, 2016 - 2028 (USD Million)
- 7.10. Latin America
- 7.10.1. Market estimates and forecast, 2016 - 2028 (USD Million)
- 7.10.2. Brazil
- 7.10.2.1. Brazil market estimates and forecast, 2016 - 2028 (USD Million)
- 7.10.3. Mexico
- 7.10.3.1. Mexico market estimates and forecast, 2016 - 2028 (USD Million)
- 7.10.4. Argentina
- 7.10.4.1. Argentina market estimates and forecast, 2016 - 2028 (USD Million)
- 7.10.5. Colombia
- 7.10.5.1. Colombia market estimates and forecast, 2016 - 2028 (USD Million)
- 7.11. Middle East & Africa
- 7.11.1. Market estimates and forecast, 2016 - 2028 (USD Million)
- 7.11.2. South Africa
- 7.11.2.1. South Africa market estimates and forecast, 2016 - 2028 (USD Million)
- 7.11.3. Saudi Arabia
- 7.11.3.1. Saudi Arabia market estimates and forecast, 2016 - 2028 (USD Million)
- 7.11.4. UAE
- 7.11.4.1. UAE market estimates and forecast, 2016 - 2028 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2020
- 8.3.4. Smiths Group plc
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Type benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Fresenius SE & Co KGaA
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Type benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. B. Braun Melsungen AG
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Type benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Baxter International Inc.
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Type benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Becton, Dickinson and Company
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Type benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. ICU Medical, Inc.
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Type benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. ACE Medical
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Type benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Terumo Corporation
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Type benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. Pfizer Inc. (Hospira)
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Type benchmarking
- 8.3.12.4. Strategic initiatives